Mitochondrial Transplantation Enhances Murine Lung Viability and Recovery after Ischemia Reperfusion Injury.
The most common cause of Acute Lung Injury (ALI) is ischemia/reperfusion injury (IRI) during which mitochondrial damage occurs. We have previously demonstrated that mitochondrial transplantation is an efficacious therapy to replace or augment mitochondria damaged by IRI, allowing for enhanced muscle viability and function in cardiac tissue. Here, we investigate the efficacy of mitochondrial transplantation in a murine lung IRI model using male C57BL/6J mice. Transient ischemia was induced by applying a microvascular clamp on the left hilum for 2 hours. Upon reperfusion mice received either vehicle or vehicle containing mitochondria either by vascular delivery (Mito V) through the pulmonary artery or by aerosol delivery (Mito Neb) via the trachea (nebulization). Sham control mice underwent thoracotomy without hilar clamping and were ventilated for 2 hours before returning to the cage. Following 24 hours recovery, lung function was assessed and lungs were collected for analysis. Our results demonstrated that at 24 hours of reperfusion dynamic compliance was significantly increased and resistance, peak inspiratory pressure, inspiratory capacity and tissue damping were significantly decreased (P<0.05) in mito groups as compared to their respective vehicles. Neutrophil infiltration, interstitial edema and apoptosis were significantly decreased (P<0.05) in mito groups as compared to vehicles. No significant differences in cytokines and chemokines between groups were shown. All functional results in Mito groups except peak inspiratory pressure in Mito Neb showed no significant differences (P>0.05) as compared to Sham. These results conclude that mitochondrial transplantation by vascular delivery or nebulization improves lung function and decreases lung tissue injury.